Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00565136
Other study ID # WC0610
Secondary ID
Status Completed
Phase Phase 1/Phase 2
First received November 27, 2007
Last updated December 11, 2015
Start date September 2007
Est. completion date December 2012

Study information

Verified date December 2015
Source ASTORA Women’s Health
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The study purpose is to gain experience with the TOPAS system, a minimally- invasively delivered self-fixating mesh for the treatment of pelvic floor weakness in women with symptoms of moderate fecal incontinence


Description:

This is a multi-center study under a common protocol. Approximately 20-30 patients will be enrolled across 5 sites in the U.S. The study population is females at least 21 years of age who have attempted but have not been satisfied with conservative therapy for their fecal incontinence symptoms. The study follow-up is two years.


Recruitment information / eligibility

Status Completed
Enrollment 29
Est. completion date December 2012
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Female
Age group 21 Years and older
Eligibility Inclusion Criteria:

- Females at least 21 years of age who have evidence of pelvic floor weakness

- Females who attempted but not been satisfied with conservative therapies such as dietary changes, dietary bulking agents, biofeedback, etc.

- Subjects, who have an external anal injury, must have some voluntary sphincter control

Exclusion Criteria:

- Subjects who are unwilling or unable to sign an Informed Consent form

- Subjects who are currently pregnant or considering future child-bearing

- Subjects who are contraindicated for surgery

- Subjects who are allergic to polypropylene mesh

- Subjects who are enrolled in a concurrent clinical trial

- Subjects with previous implantation of mesh or trauma to the pelvic area

- Subjects who engage in anal receptive intercourse

- Subjects with a significant evacuation disorder such as chronic constipation

- Subjects with Crohn's Disease, ulcerative colitis or chronic diarrhea as the primary cause for fecal incontinence

- Subjects who had a hysterectomy within 6 months prior to enrollment

- Subjects with vaginal prolapse that passes the hymen

- Subjects with complete rectal prolapse

- Subjects with a history of pelvic radiation that compromises the anal canal

- Subjects who have psychiatric disturbance or debilitation as a possible cause for fecal incontinence

- Subjects with a neurological disorder such as amyotrophic lateral sclerosis, multiple sclerosis, or brain tumor as a possible cause for fecal incontinence symptoms

- Subjects with an active pelvic infection or a recto-vaginal fistula

- Subjects who have not had a negative screening exam for colon cancer within 10 years of enrollment

- Subjects who have other inappropriate conditions as determined by the physician

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
TOPAS
A mesh sling permanently implanted to increase pelvic floor support

Locations

Country Name City State
United States St. Lukes Hospital Allentown Pennsylvania
United States Mount Auburn Hospital Cambridge Massachusetts
United States The Christ Hospital Cincinnati Ohio
United States University of Minnesota Minneapolis Minnesota
United States Sacred Heart Hospital Spokane Washington

Sponsors (1)

Lead Sponsor Collaborator
ASTORA Women’s Health

Country where clinical trial is conducted

United States, 

References & Publications (1)

Rosenblatt P, Schumacher J, Lucente V, McNevin S, Rafferty J, Mellgren A. A preliminary evaluation of the TOPAS system for the treatment of fecal incontinence in women. Female Pelvic Med Reconstr Surg. 2014 May-Jun;20(3):155-62. doi: 10.1097/SPV.000000000 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Anal Manometry: Maximum Resting Pressure Baseline (pre-treatment), 6 Month post-treatment No
Other Anal Manometry: Maximum Squeeze Pressure Baseline (pre-treatment), 6 Month post-treatment No
Other Anal Manometry: Rectal First Sensation Baseline (pre-treatment), 6 Month post-treatment No
Other Anal Manometry: Maximum Tolerable Volume Baseline (pre-treatment), 6 Month post-treatment No
Other Pudendal Nerve Terminal Motor Latency Pudendal Nerve Terminal Motor Latency is a measure of the time it takes for stimulation of the pudendal nerve to elicit contraction of the pelvic floor muscles and anal sphincter. It is a surrogate marker of pudendal nerve injuries and a means of ascertaining whether anal sphincter weakness is attributable to pudendal nerve injury, sphincter defect, or both. Baseline (pre-treatment), 6 Month post-treatment No
Primary Fecal Incontinence Incidence From Baseline (Pre-treatment) Through 24 Months Post-treatment Includes solid and liquid stools, as measured by the mean rate obtained using a subject-reported bowel diary. The 3 month post-treatment visit was the primary endpoint time period. Baseline (pre-treatment), 6 Week, 3 Month, 6 Month, 12 Month and 24 Month post-treatment No
Secondary Incidence Rate of Complications During the 24 Month Post-Treatment Follow-up Period Complications are defined as all adverse events reported during the 24 month follow-up period including serious/non-serious events and events related/not related to the device and/or procedure. Incidence rate is calculated as: (total number of adverse events reported in the 24 month follow-up period) / (total number of subjects implanted = 29) Through 24 month post-treatment Yes
Secondary Fecal Incontinence Symptoms as Measured by the Wexner Score The Wexner Score (also known as the Cleveland Clinic Florida Incontinence Score) is a subject-completed questionnaire that asks about the frequency of incontinence to gas, liquid, solid, of the need to wear pads, and of lifestyle changes (scored on a frequency scale from 0 (=absent) to 4 (daily). An overall Wexner Score is computed from these five components and a score of 0 means perfect control and 20 means complete incontinence. Baseline (pre-treatment), 6 Week, 3 Month, 6 Month, 12 Month and 24 Month post-treatment No
Secondary Fecal Incontinence Symptoms as Measured by Symptom Severity Scale in Fecal Incontinence The Symptom Severity Scale in Fecal Incontinence is a subject-completed questionnaire that asks about the symptoms of fecal incontinence in the following areas: frequency, stool composition, stool amount, and degree of urgency. The total score is measured on a 0 (best) to 13 (worst) scale. Scores of 1-6, 7-10, and 11-13 were categorized as mild, moderate, and severe fecal incontinence, respectively. Baseline (pre-treatment), 6 Week, 3 Month, 6 Month, 12 Month and 24 Month post-treatment No
Secondary Quality of Life Assessment as Measured by Fecal Incontinence Quality of Life The Fecal Incontinence Quality of Life Assessment is a subject-completed questionnaire. It is measured in each of four areas of depression (7 items), lifestyle (10 items), coping (9 items), and embarrassment (3 items). Area scores are measured on a 1 (worse) to 4 (best) scale and are each the average of their component individual item scores measured on the same scale. Baseline (pre-treatment), 3 Month, 6 Month, 12 Month and 24 Month post-treatment No
Secondary Pain Intensity as Measured by the Pain Intensity Scale The Pain Intensity Scale is a subject completed questionnaire. Scores are measured on 0 (no pain) to 10 (worst possible pain) scale. Baseline (pre-treatment), 6 Week post-treatment No
Secondary Intra- and Peri-Surgical Parameters: Length of Procedure Duration of the device implant procedure No
Secondary Intra- and Peri-Surgical Parameters: Length of Hospital Stay Length of the hospital stay for the device implant procedure No
Secondary Intra- and Peri-Surgical Parameters: Estimated Blood Loss During Implant Procedure Duration of the device implant procedure (an average of 23 minutes) Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03825575 - Sacral Neuromodulation as Treatment for Fecal Incontinence N/A
Completed NCT00605826 - A Randomized, Blinded, Multicenter Study to Evaluate NASHA/Dx for the Treatment of Fecal Incontinence N/A
Withdrawn NCT02208258 - Efficacy, Safety, and Performance Study of a Novel Device Designed to Manage Fecal Incontinence in Hospitalized Bedridden Patients With Liquid to Semi-formed Stool. N/A
Completed NCT01939821 - A Pilot Study to Evaluate Educational Programs to Improve Fecal Incontinence Care in Nursing Homes N/A
Completed NCT01957969 - French Post-Inscription Study on Sacral Neuromodulation in the Treatment of Fecal Incontinence N/A
Completed NCT01710579 - Normal Values in Ano-rectal 3D High Resolution Manometry N/A
Recruiting NCT00530933 - Tibial Nerve Stimulation for Faecal Incontinence N/A
Withdrawn NCT00522691 - Efficacy of Sacral Nerve Stimulation Before Definitive Implantation N/A
Completed NCT00677508 - Development of an Instrument to Measure Quality of Life in Children With Chronic Constipation and Soiling
Completed NCT05032534 - Examination of a New Irrigation System for Transanal Irrigation in Children With Fecal Incontinence N/A
Completed NCT05058326 - Severity of Fecal Incontinence and Manometric Values Using the Anopress® Device in Women
Completed NCT03746834 - NASHA/Dx as a Perianal Implant for the Treatment of Persistent Fecal Incontience After Anorectal Malformation Phase 4
Completed NCT00124904 - Biofeedback for Fecal Incontinence N/A
Completed NCT03028636 - LIBERATE - PRO: Eclipse™ System Registry
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1
Completed NCT05621629 - Management of FI After Surgery of ARM
Withdrawn NCT04138602 - BTL Emsella Chair Versus Sham for the Treatment of Fecal Incontinence N/A
Completed NCT03252951 - Physical Therapy for Anal Incontinence N/A
Completed NCT04478799 - Transcutaneous Posterior Nerve Stimulation inTreatment of Fecal Incontience N/A
Withdrawn NCT00307476 - Comparison of Rectal Trumpet and Standard Care N/A